{"id":"https://openalex.org/W4389248290","doi":"https://doi.org/10.1182/blood-2023-189899","title":"Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients","display_name":"Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients","publication_year":2023,"publication_date":"2023-11-02","ids":{"openalex":"https://openalex.org/W4389248290","doi":"https://doi.org/10.1182/blood-2023-189899"},"language":"en","primary_location":{"id":"doi:10.1182/blood-2023-189899","doi":"https://doi.org/10.1182/blood-2023-189899","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-189899","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5073213455","display_name":"Jan S. Rosenbaum","orcid":"https://orcid.org/0000-0002-8509-5939","observed_orcids":["https://orcid.org/0000-0002-8509-5939"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jan S. Rosenbaum","raw_affiliation_strings":["1Kurome Therapeutics Inc., Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Kurome Therapeutics Inc., Cincinnati, OH","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017419085","display_name":"Amal S. Kolt","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Amal S. Kolt","raw_affiliation_strings":["1Kurome Therapeutics Inc., Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Kurome Therapeutics Inc., Cincinnati, OH","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112269074","display_name":"Scott B. Hoyt","orcid":"https://orcid.org/0009-0009-9788-1935","observed_orcids":["https://orcid.org/0009-0009-9788-1935"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210148682","display_name":"National Center for Advancing Translational Sciences","ror":"https://ror.org/04pw6fb54","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210148682"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Scott B. Hoyt","raw_affiliation_strings":["2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210148682"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109961586","display_name":"Gregory M. Hayes","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gregory M. Hayes","raw_affiliation_strings":["1Kurome Therapeutics Inc., Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Kurome Therapeutics Inc., Cincinnati, OH","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011777763","display_name":"Brandi L. Soldo","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Brandi L. Soldo","raw_affiliation_strings":["1Kurome Therapeutics Inc., Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Kurome Therapeutics Inc., Cincinnati, OH","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014278257","display_name":"Craig J. Thomas","orcid":"https://orcid.org/0000-0001-9386-9001","observed_orcids":["https://orcid.org/0000-0001-9386-9001"]},"institutions":[{"id":"https://openalex.org/I1299303238","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238"]},{"id":"https://openalex.org/I4210148682","display_name":"National Center for Advancing Translational Sciences","ror":"https://ror.org/04pw6fb54","country_code":"US","type":"government","lineage":["https://openalex.org/I1299022934","https://openalex.org/I1299303238","https://openalex.org/I4210148682"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Craig J. Thomas","raw_affiliation_strings":["3Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"3Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD","institution_ids":["https://openalex.org/I1299303238","https://openalex.org/I4210148682"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5037735415","display_name":"Daniel T. Starczynowski","orcid":"https://orcid.org/0000-0002-5771-7462","observed_orcids":["https://orcid.org/0000-0002-5771-7462"]},"institutions":[{"id":"https://openalex.org/I1285204247","display_name":"Cincinnati Children's Hospital Medical Center","ror":"https://ror.org/01hcyya48","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1285204247"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Daniel T. Starczynowski","raw_affiliation_strings":["4Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"4Division of Experimental Hematology and Cancer Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH","institution_ids":["https://openalex.org/I1285204247"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":{"value":5000,"currency":"USD","value_usd":5000},"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":5,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"142","issue":"Supplement 1","first_page":"4152","last_page":"4152"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10309","display_name":"Acute Myeloid Leukemia Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11559","display_name":"Retinoids in leukemia and cellular processes","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12582","display_name":"Flavonoids in Medical Research","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/acute-myeloid-leukemia","display_name":"acute myeloid leukemia","score":0.9610000252723694},{"id":"https://openalex.org/keywords/myelodysplastic-syndrome","display_name":"myelodysplastic syndrome","score":1.0},{"id":"https://openalex.org/keywords/venetoclax-resistance","display_name":"venetoclax resistance","score":0.9520000219345093},{"id":"https://openalex.org/keywords/hypomethylating-agents","display_name":"hypomethylating agents","score":0.8999999761581421},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.800000011920929},{"id":"https://openalex.org/keywords/innate-immune-signaling","display_name":"innate immune signaling","score":0.8159999847412109},{"id":"https://openalex.org/keywords/flt3-mutation","display_name":"FLT3 mutation","score":0.6660000085830688},{"id":"https://openalex.org/keywords/kinase-inhibitor-selectivity","display_name":"kinase selectivity","score":0.7710000276565552},{"id":"https://openalex.org/keywords/leukemia-stem-cells","display_name":"leukemia stem cells","score":0.7070000171661377},{"id":"https://openalex.org/keywords/drug-resistance","display_name":"drug resistance","score":0.44200000166893005},{"id":"https://openalex.org/keywords/clinical-candidates","display_name":"clinical candidates","score":0.41600000858306885},{"id":"https://openalex.org/keywords/il-1-receptor","display_name":"IL-1 receptor","score":0.4909999966621399}],"concepts":[{"id":"https://openalex.org/C2779675984","wikidata":"https://www.wikidata.org/wiki/Q23671272","display_name":"Venetoclax","level":4,"score":0.6336668729782104},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.5428304076194763},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.5176942348480225},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.4742790162563324},{"id":"https://openalex.org/C2776012956","wikidata":"https://www.wikidata.org/wiki/Q17125294","display_name":"Hypomethylating agent","level":5,"score":0.4569679796695709},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.392138808965683},{"id":"https://openalex.org/C2778461978","wikidata":"https://www.wikidata.org/wiki/Q29496","display_name":"Leukemia","level":2,"score":0.3281315565109253},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.3130802512168884},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.27589327096939087},{"id":"https://openalex.org/C2777938653","wikidata":"https://www.wikidata.org/wiki/Q1088156","display_name":"Chronic lymphocytic leukemia","level":3,"score":0.20882892608642578},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.07041031122207642},{"id":"https://openalex.org/C190727270","wikidata":"https://www.wikidata.org/wiki/Q874745","display_name":"DNA methylation","level":4,"score":0.0},{"id":"https://openalex.org/C150194340","wikidata":"https://www.wikidata.org/wiki/Q26972","display_name":"Gene expression","level":3,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0},{"id":"https://openalex.org/C95444343","wikidata":"https://www.wikidata.org/wiki/Q7141","display_name":"Cell biology","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1182/blood-2023-189899","doi":"https://doi.org/10.1182/blood-2023-189899","is_oa":false,"landing_page_url":"https://doi.org/10.1182/blood-2023-189899","pdf_url":null,"source":{"id":"https://openalex.org/S200071133","display_name":"Blood","issn_l":"0006-4971","issn":["0006-4971","1528-0020"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Blood","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4310105004","https://openalex.org/W4376507174","https://openalex.org/W4310105249","https://openalex.org/W4386725819","https://openalex.org/W2953131727","https://openalex.org/W4362592781","https://openalex.org/W2337548752","https://openalex.org/W4412957781","https://openalex.org/W2615280314","https://openalex.org/W4389231951"],"abstract_inverted_index":{"Leukemic":[0],"cells":[1,404],"exhibit":[2],"dysregulation":[3],"of":[4,33,65,107,165,180,244,302,317,320,330,336,377,402,414,445,495,527],"innate":[5],"immune":[6],"signaling":[7,36,224,233],"pathways":[8,13,44,247],"upon":[9],"diagnosis,":[10],"and":[11,26,49,70,74,105,109,116,141,183,188,216,238,254,379,382,458,475,507,532],"these":[12,42,430],"become":[14],"further":[15],"activated":[16,40,332],"in":[17,41,46,81,94,148,170,196,281,309,370,462,487,522,529,539],"drug":[18],"resistance.":[19],"The":[20,394],"Interleukin-1":[21],"receptor":[22,246],"associated":[23],"kinase":[24,29,175,192,205],"1":[25],"4":[27],"(IRAK1/IRAK4)":[28],"complex":[30],"is":[31,131,194,208,300,314,367,398,534],"part":[32],"a":[34,102,132,350,442],"critical":[35],"node":[37],"that":[38,88,137,290,341,366,411,433,516],"becomes":[39],"dysregulated":[43],"(reviewed":[45],"J":[47],"Bennett":[48,124,388],"DT":[50],"Starczynowski,":[51],"Curr":[52],"Opin":[53],"Hematol":[54],"2022).":[55],"IRAK4":[56,92,117,145,255,287,333,337,356,452],"inhibitors":[57,93],"are":[58,416],"currently":[59,535],"under":[60],"investigation":[61],"for":[62,405],"the":[63,95,110,149,155,166,171,226,236,277,318,331,342,436,463,488,496],"treatment":[64,401],"Acute":[66],"Myeloid":[67],"Leukemia":[68],"(AML)":[69],"Myelodysplastic":[71],"Syndrome":[72],"(MDS)":[73],"have":[75,85,347,359],"shown":[76],"encouraging,":[77],"though":[78],"modest":[79],"responses":[80,90],"clinical":[82,505,525],"studies.":[83],"We":[84,358],"recently":[86],"demonstrated":[87],"limited":[89],"to":[91,112,118,327,418,438,460,481,537],"leukemic":[96],"setting":[97],"can":[98],"be":[99,439,519],"explained":[100],"by":[101,276],"compensated":[103],"upregulation":[104],"activation":[106],"IRAK1,":[108,186],"need":[111],"inhibit":[113,493],"both":[114,235,252],"IRAK1":[115,253,292],"achieve":[119],"maximal":[120],"therapeutic":[121,142],"efficacy":[122,143,459],"(JR":[123,387],"et.":[125,389,425],"al.,":[126,390],"Blood":[127,391],"2023":[128,392],"https://doi.org/10.1182/blood.2022018718).":[129,393],"KME-0584":[130,159,229,267,345,434,454,490,528],"highly":[133,368],"potent":[134],"IRAK1/IRAK4/panFLT3":[135],"inhibitor":[136,146,288,344],"exhibits":[138,160,455],"superior":[139,456],"potency":[140,204,285,308,457],"vs.":[144,163,199],"compounds":[147,220,289],"FLT3":[150,156,189,263],"WT":[151],"as":[152,154,168,274,295],"well":[153],"mutant":[157],"setting.":[158],">100-fold":[161],"selectivity":[162,193],"89%":[164],"Kinome":[167],"measured":[169,275],"Reaction":[172],"Biology":[173],"374":[174],"panel,":[176],"with":[177,283,372,383,408,472],"an":[178,355,362,384],"IC50":[179],"23,":[181],"<1.29,":[182],"<0.5nM":[184],"at":[185,503],"IRAK4,":[187],"respectively.":[190],"Higher":[191],"seen":[195],"cell-based":[197],"assays":[198],"biochemical":[200],"assays,":[201],"where":[202],"high":[203,307],"antagonist":[206],"activity":[207,293,299,348],"also":[209],"observed":[210,315],"against":[211],"PHKg1,":[212],"PDGFR\u03b2,":[213],"RET,":[214],"CLK1,":[215],"CLK4.":[217],"While":[218],"IRAK4-selective":[219],"fully":[221],"antagonize":[222],"NF-\u03baB":[223,232,250],"through":[225,234],"TLR":[227,237],"pathway,":[228],"completely":[230],"inhibits":[231,268],"IL1-receptor":[239],"pathways,":[240],"indicating":[241],"complete":[242],"inhibition":[243],"multiple":[245,479],"converging":[248],"on":[249],"requires":[251],"antagonism.":[256],"In":[257],"primary":[258,310],"patient":[259,303,311,352],"cell":[260,271,312],"lines":[261,313],"from":[262,510],"wildtype":[264],"(WT)":[265],"patients,":[266],"leukemia":[269],"stem":[270],"progenitor":[272],"function":[273],"colony":[278],"formation":[279],"assay":[280],"methylcellulose":[282],"higher":[284],"than":[286,354,449],"lack":[291],"such":[294],"CA-4948":[296],"(Emavusertib).":[297],"This":[298],"independent":[301,316],"mutational":[304],"status.":[305],"Importantly,":[306],"presence":[319],"U2AF1":[321],"or":[322,484,498],"SF3B1":[323],"spliceosome":[324],"mutations":[325],"known":[326],"drive":[328],"expression":[329],"Long":[334],"isoform":[335],"(Fig":[338],"1),":[339],"implying":[340],"IRAK1/4/panFLT3":[343],"will":[346],"across":[349,441,478],"broader":[351,443],"population":[353],"inhibitor.":[357],"previously":[360,450],"described":[361],"IRAK1/4":[363,395],"gene":[364,396],"signature":[365,397],"expressed":[369],"patients":[371,448],"myelomonocytic":[373],"subtypes":[374,413],"(M4":[375],"FAB)":[376],"adult":[378],"pediatric":[380],"AML":[381,415,531],"antecedent":[385],"MDS":[386],"reversed":[399],"after":[400,468],"THP1":[403],"24":[406],"hours":[407],"KME-0584.":[409],"Given":[410],"monocytic-like":[412],"resistant":[417],"Venetoclax":[419],"plus":[420],"Azacitidine":[421],"(VEN/AZA)":[422],"(S":[423],"Pei":[424],"al.":[426],"Cancer":[427],"Discovery,":[428],"2020),":[429],"data":[431],"suggest":[432,515],"has":[435],"potential":[437],"effective":[440],"range":[444],"relapsed/refractory":[446,530],"AML/MDS":[447],"examined":[451],"inhibitors.":[453],"gilteritinib":[461],"FLT3-ITD":[464],"(D835Y)":[465],"xenograft":[466],"model":[467],"QD":[469,483],"oral":[470,476],"dosing,":[471],"sufficient":[473],"PK":[474],"bioavailability":[477],"species":[480],"support":[482],"BID":[485],"dosing":[486],"clinic.":[489],"does":[491],"not":[492],"any":[494],"major":[497],"minor":[499],"cytochrome":[500],"P450":[501],"enzymes":[502],"anticipated":[504],"concentrations":[506],"early":[508],"indication":[509],"ongoing":[511],"GLP":[512],"toxicology":[513],"studies":[514],"it":[517],"could":[518],"safely":[520],"administered":[521],"humans.":[523],"A":[524],"study":[526],"HR-MDS":[533],"planned":[536],"start":[538],"1H":[540],"2024.":[541]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-12-02T00:00:00"}